NextCure (NXTC) CFO receives 14,670 employee stock option grant

Rhea-AI Filing Summary

NextCure, Inc. insider filing shows a new stock option grant to its Chief Financial Officer, Steven P. Cobourn. On January 30, 2026, he received an employee stock option to buy 14,670 shares of NextCure common stock at an exercise price of $10.85 per share.

According to the vesting schedule, one fourth of the option vests on January 30, 2027, with the remaining three fourths vesting in 36 equal monthly installments starting February 28, 2027. This type of award is a standard form of equity compensation that links executive pay to the company’s future stock performance.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Cobourn Steven P.

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (Right to Buy)	14,670	$0.00	--

Holdings After Transaction: Employee Stock Option (Right to Buy) — 14,670 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cobourn Steven P.

(Last) (First) (Middle)

C/O NEXTCURE, INC.

9000 VIRGINIA MANOR ROAD, SUITE 200

(Street)

BELTSVILLE MD 20705

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NextCure, Inc. [ NXTC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/30/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$10.85	01/30/2026		A		14,670		(1)	01/29/2036	Common Stock	14,670	$0	14,670	D

Explanation of Responses:

1. One fourth of the option vests on January 30, 2027. The remainder vests in 36 monthly installments beginning on February 28, 2027.

	/s/ Steven P. Cobourn	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did NextCure (NXTC) report in this Form 4?

NextCure reported a stock option grant to its Chief Financial Officer, Steven P. Cobourn. He received options to buy 14,670 shares of common stock, recorded as a derivative security transaction dated January 30, 2026, under transaction code “A” for award or grant.

How many NextCure (NXTC) shares are covered by the CFO’s new option grant?

The employee stock option granted to NextCure’s CFO covers 14,670 shares of common stock. This figure represents the full number of shares underlying the derivative security and matches the number of derivative securities beneficially owned following the reported transaction in the filing.

What is the exercise price of the CFO’s stock options at NextCure (NXTC)?

The employee stock option granted to the NextCure CFO has an exercise price of $10.85 per share. This is the price he must pay per share to convert the option into common stock if he chooses to exercise the award in the future.

When do the newly granted NextCure (NXTC) options to the CFO vest?

The vesting is time-based. One fourth of the option vests on January 30, 2027. The remaining three fourths vest in 36 equal monthly installments beginning on February 28, 2027, creating a multi-year vesting schedule that encourages continued executive service.

Who is the insider receiving the stock option grant at NextCure (NXTC)?

The recipient is Steven P. Cobourn, who serves as Chief Financial Officer of NextCure, Inc. The Form 4 identifies him as an officer, not a director or 10% owner, and reports that he holds the newly granted options as a direct beneficial owner.

Is the CFO’s ownership in this NextCure (NXTC) Form 4 direct or indirect?

The filing shows that the 14,670 employee stock options are held as a direct ownership position. The ownership form is marked “D” for direct, and no footnotes indicate that the options are held through a separate entity, trust, or other indirect structure.